Compare Abeona Therapeutics Inc (ABEO) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while iShares 3 7 Year Treasury Bond ETF trades at $116.64. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | IEI | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Fixed Income |
52-Week High | $7.23 | $120.72 |
52-Week Low | $4.17 | $116.67 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $117.20 with minimal daily movement (+0.08%). Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. The ETF focuses exclusively on intermediate-term U.S. Treasury debt, offering lower volatility compared to corporate bond alternatives. Recent dividend payments of $0.36-$0.37 demonstrate consistent income distribution to investors.
The outlook for IEI remains heavily dependent on Federal Reserve policy direction amid ongoing inflation concerns. While Treasury-focused ETFs provide safety during market volatility, rising rate expectations pose headwinds for bond prices. The fund's government debt exposure offers stability but may underperform higher-yielding alternatives in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
